Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, with a subsidiary in Montreal, Quebec, Canada. It is dedicated to the discovery and early stage development of 1st in class G Protein-Coupled Receptors (GPCRs) / Transmembrane based drugs.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
• The developement of collaborative partnerships with Pharma/Biotechs leveraging the knowledge and expertise of its R&D team and its two validated proprietary technologies BioSensAll™ (signalling signatures) and DTect-All™ (allosteric modulation)
• The development of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS, oncology and rare diseases through its own R&D and in-licensing external early-stage programmes
• The valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies